TransCode Therapeutics, Inc. engages in the development and commercialization of drugs and diagnostics.Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company was incorporated in 2016 and is based in Boston, Massachusetts.